Phase 3
Completed N=61
Pramipexole Conversion to Ropinirole Controlled Release (CR)
Source: ClinicalTrials.gov NCT00275275 ↗Enrolled (actual)
61
Serious AEs
0.0%
Results posted
Aug 2012
Primary outcomePrimary: Adverse Effects Experienced — 29; 43 number of events
Summary
A conversion study of Mirapex (pramipexole) to Requip (ropinirole) controlled release (CR) in patients with Parkinson's disease to determine the appropriate conversion ratio and side effects related to the drug.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Adverse Effects Experienced |
29; 43 | — |
| SECONDARY Number of Dose Adjustments |
0.6; 1.3 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of Parkinson Disease
- Currently taking pramipexole
- Never have taken Requip CR
Exclusion Criteria
- Can not have significant adverse effects to standard Requip
- Can not have atypical PD due to drugs, metabolic disorders, encephalitis or degenerative diseases
- Can not have unstable medical conditions
- Can not be taking concurrent monoamine oxidase inhibitors except for selegiline (10mg per day or less)
- Female patients of childbearing potential must be using an effective method of contraception.
- Can not be pregnant or lactating.
This may not be a complete list; there may be additional criteria which may apply.
Data sourced from ClinicalTrials.gov (NCT00275275). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.